Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|RTOG-0522||RTOG||A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation; Cisplatin and Cetuximab (C225) [Followed by Surgery for Selected Patients] For Stage III and IV Head and Neck Carcinomas<br>||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA2186||ECOG-ACRIN||A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)||Adult CIRB - Late Phase Emphasis||Available to Open|
|ANZGOG-0902-GOG-0274||GOG||A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)||Adult CIRB - Late Phase Emphasis||Available to Open|
|CALGB-90104||CALGB||A Randomized Phase III Study Comparing Sequential Chemotherapy (AG-TP) to Cisplatin and Gemcitabine as Adjuvant Treatment After Cystectomy for Transitional Cell Carcinoma of the Bladder||Adult CIRB - Late Phase Emphasis||Completed|
|NRG-GY005||NRG||A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone; or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian; fallopian tube; or primary peritoneal cancer (COCOS)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A071601||Alliance||Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas||Adult CIRB - Late Phase Emphasis||Available to Open|
|ACOSOG-Z1031||ACSOG||A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily); Letrozole (2.5 mg); or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-LU006||NRG||Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy with or without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM)||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GI005||NRG||Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1605||SWOG||Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|